



IFw

Docket No. TIP0045USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Verschueren Wim Gaston et al.

Serial No. : 10/554712 Art Unit:

Filed : 04/27/2004 Examiner:

For : HIV Integrase Inhibitors

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 16, 2006

(Date of Deposit)

Alana G. Kriegsman

(Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/

(Signature)

August 16, 2006

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TIP0045USPCT/agk. This form is submitted in triplicate.

Respectfully submitted,

/Alana G. Kriegsman/
Alana G. Kriegsman
Reg. No. 41,747
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: August 16, 2006



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/554712
Filing Date	04/27/2004
First Named Inventor	Verschueren Wim Gaston
Group Art Unit	
Examiner Name	
Attorney Docket Number	TIP0045USPCT

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		EP	0459449	B1	Shionogi & Co., LTD.	12-21-1994		
		EP	0499299	B1	NanoSystems LLC	08-16-2000		
		EP	0721331	B1	AstraZenecaAB	12-05-2001		
		WO	94/05263	A1	Janssen Pharmaceutica N.V.	03-17-1994		
		WO	97/44014	A1	Janssen Pharmaceutica N.V.	11-27-1997		
		WO	98/42318	A1	Janssen Pharmaceutica N.V.	10-01-1998		
		WO	02/030426	A1	Merck & Co., Inc.	04-18-2002		
		WO	02/030930	A2	Merck & Co., Inc.	04-18-2002		
		WO	02/030931	A2	Merck & Co., Inc.	04-18-2002		
		WO	02/036734	A2	Merck & Co., Inc.	05-10-2005		
		WO	02/055079	A2	Merck & Co., Inc.	07-18-2002		
		WO	2004/035576	A2	Gilead Sciences, Inc.	04-29-2004		
		WO	2004/035577	A2	Gilead Sciences, Inc.	04-29-2004		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2	Application Number	10/554712
	Filing Date	04/27/2004
	First Named Inventor	Verschueren Wim Gaston
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	TIP0045USPCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BENET, L. et al., "Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination.", <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , Eighth Edition, pages 13-20, McGraw-Hill Inc.	
		CROSS, et al., "Rules For The Nomenclature of Organic Chemistry, Section E: Stereochemistry." <i>Pure & Applied Chemistry</i> , 1976, pages 13-30, Vol. 45., Pergamon Press, Great Britain.	
		DENIAU et al., "Synthesis of 3-alkyl-1-isindolinones By Alkylation of a Benzotriazolyl Substituted N-dimethylamino-phthalimidine.", <i>Tetrahedron</i> , 2001, pages 2581-2588, Vol. 57.	
		GOTO et al., "The Thermally-Controlled Chemoselective Reduction of 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione with Sodium Borohydride.", <i>Bulletin of the Chemical Society of Japan</i> , 1987, pages 4178-4180, Vol. 60, No.11.	
		HARTMANN et al., "Preparation of Naphthoquinone Imines As NIR Dyes.", <i>Tetrahedron</i> , 1995, pages 4655-4664, Vol. 51, No. 16.	
		HERTOGS, K. et al., "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs.", <i>Antimicrobial Agents and Chemotherapy</i> , Feb. 1998, pages 269-276, Vol. 42, No. 2.	
		HEYNS et al., "Über Die Synthese Von 2,3-Dialkylpyrazinen.", <i>Chemische Berichte</i> , 1981, pages 240-245, Vol. 114, English Abstract included.	
		JENKINS et al., "A Soluble Active Mutant of HIV-1 Integrase.", <i>The Journal of Biological Chemistry</i> , March 29, 1996, pages 7712-7718, Vol. 271, No. 13.	
		KAPPE et al., "Generation and Subsequent Cycloaddition Chemistry of α -Amino Isobenzofurans Formed by Cationic Cyclization.", <i>Tetrahedron Letters</i> , 1995, pages 9285-9288, Vol. 36, No. 51.	
		KREPELKA et al., "Synthesis and Antineoplastic Effects of Some N-Substituted Imides of 1-Substituted 4-Aryl-Naphthalene-2,3-Dicarboxylic Acids.", <i>Collection Czechoslovak Chem. Commun.</i> , 1982, pages 304-314, Vol. 47(1).	
		MILEWSKA et al., "Synthesis of Lactams by Regioselective Reduction of Cyclic Dicarboximides.", <i>Synthesis</i> , December 1996, pages 1485-1488.	
		MURRAY et al., "Facile Access to Novel 1,4-Dihydroxynaphthalene-2,3-dicarboximides and Heterofused Analogs.", <i>Synthesis</i> , 1996, pages 1180-1182, Vol.10.	
		OHWADA et al., "Reaction of N-Aminophthalimide Derivatives With Aluminum Chloride In Benzene.", <i>Heterocycles</i> , 1997, pages 225-233, Vol. 46.	
		PADWA et al., "Studies Dealing With the Cycloaddition/Ring Opening/Elimination Sequence of 2-Amino-Substituted Isobenzofurans.", <i>J. Org. Chem.</i> , 1997 pages 2786-2797, Vol. 62.	
		PASSANNANTI et al., "The Synthesis of Narciclastic Aldehyde and Related Isocarbostyrils.", <i>Journal of Heterocyclic Chemistry</i> , 1977, pages 103-106, Vol. 14, No. 1.	
		ROGGO et al., "Novel Spirodihydrobenzofuranlactams as Antagonists of Endothelin and as Inhibitors of HIV-1 Protease Produced by <i>Strachybotrys</i> sp.- I. Fermentation, Isolation and Biological Activity.", <i>The Journal of Antibiotics</i> , 1996, pages 13-19, Vol. 49 No. 1.	
		SPIESSENS et al., "Preparation and Structural Assignments of Some Isomeric 2,3-Disubstituted Pyridines.", <i>Bull. Soc. Chem. Belg.</i> , 1980, pages 205-231, Vol. 89, No. 3.	
		TROLL et al., "Darstellung Und Reationen Von 1,3-Bis-Trimethylsilyloxy-Isobenzofuranen Und -Isoindolen.", <i>Tetrahedron Letters</i> , 1981, pages 3497-3500, Vol. 22, No.36, Pergamon Press Ltd., English Abstract included.	
		TROLL et al., "Darstellung Und Reationen Von 1,3-Bis-(Trimethylsilyloxy)-Isobenzofuranen.", <i>Tetrahedron Letters</i> , 1984, pages 2981-2984, Vol. 25, No. 28, English Abstract included.	
		UEDA et al., "Synthesis of Pyrazolone Derivatives. XXVI. 1) Reaction of 1-Methyl-2-phenyl-1,2,3,10-tetrahydro[6,7]thiepio[3,4-c]pyrazole-3,4-dione with Dimethyl Acetylenedicarboxylate.", <i>Chem. Pharm. Bulletin</i> , 1976, pages 596-606, Vol. 24, No. 4.	
		VORS, Jean-Pierre, "A Convenient Synthesis of Pyridazine-3,4-dicarboxylic Acid by a Hetero Diels-Alder Reaction.", <i>Journal of Heterocyclic Chemistry</i> , 1990, pages 579-582, Vol. 27, No.3.	
		XP-002256901, Database Accession No. BRN:145097, <i>Rocz. Chem.</i> , 1996, page 653, 657,661, Vol. 36.	
		XP-002256902, Database Accession No. BRN:148975, <i>Rocz. Chem.</i> , 1962, page 653, 657, 661, Vol. 36.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

